Market Place
Sourcing Support
Enterome Presents Data For Colorectal Cancer At ESMO IO 2024
11 Dec 2024 //
GLOBENEWSWIRE
Enterome EO2463 Shows Early Response In Follicular Lymphoma
10 Dec 2024 //
GLOBENEWSWIRE
Enterome Hosts Webinar on Phase 1/2 Data for EO2463
13 Nov 2024 //
BUSINESSWIRE
Enterome to Present EO2463 Data at ASH Annual Meeting 2024
06 Nov 2024 //
GLOBENEWSWIRE
Enterome to Participate in the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Enterome updates clinical data from ongoing EONHL1-20/SIDNEY trial EO2463
27 May 2024 //
PHARMABIZ
Enterome Eho2463 High Response Rate: Indolent Nhl At Asco 2024 Featured
24 May 2024 //
GLOBENEWSWIRE
Enterome to Present EO2463 Data in B-cell Lymphoma at ASCO 2024
25 Apr 2024 //
GLOBENEWSWIRE
Enterome Announces Successful Completion of Phase 2 ROSALIE Study
17 Apr 2024 //
GLOBENEWSWIRE
Enterome Announces Presentation on OncoMimics Approach to Cancer Immunotherapy
06 Mar 2024 //
GLOBENEWSWIRE
Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors
18 Dec 2023 //
GLOBENEWSWIRE
Enteromes Immunotherapy EO2401 Improves Survival Rate in Glioblastoma
20 Nov 2023 //
GLOBENEWSWIRE
Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of EO2401
13 Nov 2023 //
GLOBENEWSWIRE
Enterome Presents Immune-Monitoring Data on EO2401
01 Nov 2023 //
GLOBENEWSWIRE
Enterome Selected to Leukemia & Lymphoma Society™s Therapy Acceleration Program
30 Oct 2023 //
GLOBENEWSWIRE
Enterome to Present Clinical Progress on its OncoMimics Pipeline
25 Oct 2023 //
GLOBENEWSWIRE
Enterome Presents Positive Data from Phase 1/2 SPENCER Trial of EO2401
23 Oct 2023 //
GLOBENEWSWIRE
Enterome to Present Data on EO2401 in Adrenal Tumors at ESMO
16 Oct 2023 //
GLOBENEWSWIRE
Enterome announces first patient dosed in Phase 2 trial with EO2040
11 Jul 2023 //
GLOBENEWSWIRE
Enterome announces first patient dosed in a Ph1/2 trial third OncoMimics, EO4010
30 Jun 2023 //
GLOBENEWSWIRE
Positive profile for Enterome`s lymphoma candidate
15 Jun 2023 //
PHARMATIMES
Enterome`s EO2463, demonstrates early efficacy in Phase 1/2 trial
14 Jun 2023 //
GLOBENEWSWIRE
Enterome announces sustained positive clinical outcomes with EO2401
31 May 2023 //
GLOBENEWSWIRE
Enterome forms Scientific Advisory Board & Medical Advisory Group its OncoMimics
09 May 2023 //
GLOBENEWSWIRE
Enterome`s Management to Attend Upcoming Meetings
10 Mar 2023 //
GLOBENEWSWIRE
Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating EO2401
12 Dec 2022 //
PRNEWSWIRE
Enterome presents two posters on Phase 2 data of EO2401 at ESMO IO 2022
07 Dec 2022 //
PRNEWSWIRE
Enterome to present data from Phase 1/2 trial of EO2401 in ROSALIE study
16 Nov 2022 //
PRNEWSWIRE
Enterome`s OncoMimics™ peptide-based immunotherapy EO2401
10 Nov 2022 //
PRNEWSWIRE
Enterome to present updated safety data from its Phase 1/2 trial of EO2401
07 Nov 2022 //
PRNEWSWIRE
Enterome presents further efficacy data on its therapeutic cancer vaccine EO2401
12 Sep 2022 //
PRNEWSWIRE
Enterome to present updates on EO2401,OncoMimics therapeutic cancer vaccine
06 Sep 2022 //
PRNEWSWIRE
Enterome and Nestlé Health Science to work on food allergies and IBD
18 Jul 2022 //
LABIOTECH
Enterome presents proof-of-concept immune response data
06 Jun 2022 //
PRNEWSWIRE
Enterome presents POC immune response data from PI/II trial with EO2401
06 Jun 2022 //
PRNEWSWIRE
Enterome to present 3 abstracts on novel OncoMimics cancer immunotherapies
26 May 2022 //
PRNEWSWIRE
Enterome to present promising clinical progress on its OncoMimics pipeline
23 May 2022 //
PRNEWSWIRE
Enterome to present world first clinical data with EO2401
19 May 2022 //
PRNEWSWIRE
Enterome to present the significant potential of its Mimicry concept
05 Apr 2022 //
PRNEWSWIRE
Enterome`s first patient dosed in Phase 1/2 trial with OncoMimicsâ„¢, EO2463
12 Jul 2021 //
PRNEWSWIRE
Enterome`s first patient dosed in Phase 1/2 trial with OncoMimicsâ„¢, EO2463
12 Jul 2021 //
PRNEWSWIRE
Enterome`s first patient dosed in Phase 1/2 trial with OncoMimics™, EO2463
12 Jul 2021 //
PRNEWSWIRE
Enterome Receives FDA IND Clearance for EO2463, an `OncoMimic`
24 Mar 2021 //
PRNEWSWIRE
Enterome strengthens its leadership team with the appointment of Anne
09 Mar 2021 //
PRNEWSWIRE
Enterome announces 1st patient dosed in PhIIa trial of sibofimloc
22 Sep 2020 //
PRNEWSWIRE
Enterome to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
21 Sep 2020 //
BIOSPACE
Enterome scientists contribute to extensive new genomic and proteomic catalog
03 Aug 2020 //
PRNEWSWIRE
Enterome initiates first clinical trial EO2401 an innovative microbiome-antigen
29 Jul 2020 //
PRNEWSWIRE
Enterome Completes €46.3 Million ($52.6 Million) Financing Therapeutic Pipeline
25 Jun 2020 //
PRNEWSWIRE
Enterome Completes €46.3 Million ($52.6 M) Financing to Progress the DeVP
24 Jun 2020 //
PRNEWSWIRE
